Psychedelics have become an area of increasing investment and drug development activities as an emerging group of companies is working to develop these compounds as treatments for neurologic and psychiatric conditions. That’s because of the ability of these drugs to target serotonin, which plays a critical role in the regulation of cognitive function, emotions, memory, and the sleep-wake cycle. Bright Minds Biosciences is developing a pipeline of psychedelics as the next generation of serotonin modulators to treat neuropsychiatric, seizure, and pain disorders by restoring serotonin activity to normal levels. We spoke to Gideon Shapiro, vice president of discovery at Bright Minds Biosciences, about the role serotonin plays in the health of the brain, why psychedelics have emerged as compelling therapeutics for a range of conditions, and the company’s pipeline of drugs in development.